102 related articles for article (PubMed ID: 7503571)
1. A transgenic mouse model provides a novel biological assay of topical glucocorticosteroid potency.
Katchman SD; Del Monaco M; Wu M; Brown D; Hsu-Wong S; Uitto J
Arch Dermatol; 1995 Nov; 131(11):1274-8. PubMed ID: 7503571
[TBL] [Abstract][Full Text] [Related]
2. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
[TBL] [Abstract][Full Text] [Related]
3. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
[TBL] [Abstract][Full Text] [Related]
4. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
Meyer E; Smith EW; Haigh JM; Kanfer I
Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
[TBL] [Abstract][Full Text] [Related]
5. Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers.
Kecskés A; Jahn P; Wendt H; Kleine-Kuhlmann R; Lange L
Arzneimittelforschung; 1993 Feb; 43(2):144-7. PubMed ID: 8457237
[TBL] [Abstract][Full Text] [Related]
6. The hairless mouse as a model for study of local and systemic atrophogenic effects following topical application of corticosteroids.
van den Hoven WE; van den Berg TP; Korstanje C
Acta Derm Venereol; 1991; 71(1):29-31. PubMed ID: 1676210
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
Lee CS; Koo J
J Drugs Dermatol; 2009 Aug; 8(8):751-5. PubMed ID: 19663113
[TBL] [Abstract][Full Text] [Related]
8. Epidermal thinning: evaluation of commercial corticosteroids.
Wrench R
Arch Dermatol Res; 1980; 267(1):7-24. PubMed ID: 7387177
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical availability of clobetasol-17-propionate from cream and ointment.
Dyderski S; Grześkowiak E; Szałek E; Mrzygłód A
Acta Pol Pharm; 2001; 58(6):435-8. PubMed ID: 12197615
[TBL] [Abstract][Full Text] [Related]
10. Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis.
Oranje AP; Verbeek R; Verzaal P; Haspels I; Prens E; Nagelkerken L
Br J Dermatol; 2009 Jan; 160(1):54-61. PubMed ID: 18795918
[TBL] [Abstract][Full Text] [Related]
11. 0.05% clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations increase skin surface roughness: a possible dissociation of unwanted epidermal and dermal effects.
Kerscher MJ; Korting HC; Mehringer L; Mätzig R
Skin Pharmacol; 1996; 9(2):120-3. PubMed ID: 8722606
[TBL] [Abstract][Full Text] [Related]
12. Diflucortolone valerate (Nerisona): a comparative vasoconstriction test in artificially induced hyperemia of the skin.
Reckers R; Wendt H
Clin Ther; 1980; 3(3):190-3. PubMed ID: 7459929
[TBL] [Abstract][Full Text] [Related]
13. Induction of drug metabolising enzymes in the skin by topical steroids.
Finnen MJ; Herdman ML; Shuster S
J Steroid Biochem; 1984 May; 20(5):1169-73. PubMed ID: 6610079
[TBL] [Abstract][Full Text] [Related]
14. A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus. A Phase IV, randomized, observer-blinded, parallel group clinical trial.
Campisi G; Giandalia G; De Caro V; Di Liberto C; Aricò P; Giannola LI
Br J Dermatol; 2004 May; 150(5):984-90. PubMed ID: 15149513
[TBL] [Abstract][Full Text] [Related]
15. The penetration of 0.005% fluticasone propionate ointment in eyelid skin.
Tan MH; Lebwohl M; Esser AC; Wei H
J Am Acad Dermatol; 2001 Sep; 45(3):392-6. PubMed ID: 11511836
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and fluocinonide.
Ong JT; Poulsen BJ; Akers WA; Scholtz JR; Genter FC; Kertesz DJ
Arch Dermatol; 1989 Dec; 125(12):1662-5. PubMed ID: 2589861
[TBL] [Abstract][Full Text] [Related]
17. Eumovate (clobetasone butyrate) 0.05% cream with its moisturizing emollient base has better healing properties than hydrocortisone 1% cream: a study in nickel-induced contact dermatitis.
Parneix-Spake A; Goustas P; Green R
J Dermatolog Treat; 2001 Dec; 12(4):191-7. PubMed ID: 12241627
[TBL] [Abstract][Full Text] [Related]
18. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
[TBL] [Abstract][Full Text] [Related]
19. Topical corticosteroids.
Med Lett Drugs Ther; 1991 Nov; 33(857):108-10. PubMed ID: 1943979
[No Abstract] [Full Text] [Related]
20. Peristomal dermatoses: a novel indication for topical steroid lotions.
Lyon CC; Smith AJ; Griffiths CE; Beck MH
J Am Acad Dermatol; 2000 Oct; 43(4):679-82. PubMed ID: 11004626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
